Key facts
- It has raised $46.4M across 2 recorded rounds; the latest was Early Stage VC ($30.0M) in Nov 2022.
- Cue Biopharma has filed 3 Form Ds with the SEC since 2016, most recently Nov 2022 ($30.0M sold to 64 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Cue Biopharma
Create free account
No card required
Funding rounds
2 roundsAbout Cue Biopharma
PA Mark — not yet priced
Cue Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Cue Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Cue Biopharma in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.